 CARMIEL, Israel, Aug. 2, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration FDA to discuss the Complete Response Letter CRL dated April 27, 2021 regarding the Biologics License Application BLA for pegunigalsidase alfa PRX-102 for the proposed treatment of adult patients with Fabry disease. The Type A Meeting is expected to occur within 30 days of the FDAs receipt of the meeting request. 